SIGA Share Price

Open 5.01 Change Price %
High 5.05 1 Day -0.20 -4.00
Low 4.72 1 Week 0.00 0.00
Close 4.80 1 Month 0.80 20.00
Volume 61804 1 Year 2.30 92.00
52 Week High 5.24
52 Week Low 0.00
SIGA Important Levels
Resistance 2 5.11
Resistance 1 4.98
Pivot 4.86
Support 1 4.62
Support 2 4.49
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

SIGA Technologies Inc. (NASDAQ: SIGA)

SIGA Technical Analysis 5
As on 31st Oct 2017 SIGA Share Price closed @ 4.80 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 3.24 & Strong Buy for SHORT-TERM with Stoploss of 3.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
SIGA Target for December
1st Target up-side 5.94
2nd Target up-side 6.75
3rd Target up-side 7.55
1st Target down-side 3.66
2nd Target down-side 2.85
3rd Target down-side 2.05
SIGA Other Details
Segment EQ
Market Capital 152333136.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.siga.com
SIGA Address
SIGA
660 Madison Avenue
Suite 1700
New York, NY 10065
United States
Phone: 212-672-9100
Fax: 212-697-3130
SIGA Latest News
Interactive Technical Analysis Chart SIGA Technologies Inc. ( SIGA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on SIGA Technologies Inc.
SIGA Business Profile
SIGA Technologies, Inc. (SIGA) is a pharmaceutical company specializing in the development and commercialization of pharmaceutical solutions for some of the lethal disease-causing pathogens in the world - smallpox, Ebola, dengue, Lassa fever and other dangerous viruses. Its business is to discover, develop, manufacture and successfully commercialize drugs to prevent and treat these high-priority threats. The Company's focuses to disarm dreaded viral diseases and create robust, modern biodefense countermeasures. The Company�s product include ST-246, is an orally administered antiviral drug that targets orthopoxviruses. The Company�s lead product, ST-246, is an orally administered antiviral drug that targets orthopoxviruses. On May 13, 2011, it signed the BARDA Contract pursuant to which it agreed to deliver two million courses of ST-246 to the Strategic Stockpile.